07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas and...
07:00 , Mar 14, 2013 |  BC Innovations  |  Cover Story

Squaring the RNA circle

Two European teams have provided the strongest evidence to date that circular RNAs are widely expressed in human cells and have clear regulatory functions.1,2 The biomedical relevance of circular RNAs remains largely unexplored, but the...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; neurology MicroRNA-7 (miR-7); cerebellar degeneration-related protein 1 antisense (ciRS-7; CDR1as) In silico and cell culture studies...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

MiReven, Silence Therapeutics preclinical data

In vitro, miR-7-5p significantly inhibited the migration and invasion of metastatic melanoma cells. The product is a miRNA targeting insulin receptor substrate 2 (IRS2), an activator of protein kinase B (PKB; PKBA; AKT; AKT1)....
07:00 , Aug 27, 2012 |  BC Week In Review  |  Company News

MiReven, Silence Therapeutics deal

Silence partnered with MiReven to develop formulations of MiReven's microRNA-7 (miR-7) using Silence's lipid-based delivery technologies. The partners will evaluate the compound in models of prostate and lung cancers and melanoma. Silence will receive...
07:00 , Aug 27, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Dynavax Technologies Corp. (NASDAQ:DVAX) was off $0.13 to $3.54 last week after EMA accepted for review an MAA for Heplisav to prevent HBV infection caused by all known subtypes in adults ages 18-70 years...
00:01 , Aug 23, 2012 |  BC Extra  |  Company News

Silence, MiReven in microRNA deal

Silence Therapeutics plc (LSE:SLN) partnered with MiReven Pty. Ltd. (Perth, Australia) to develop formulations of MiReven's microRNA-7 (miR-7) using Silence's lipid-based delivery technologies. The partners will evaluate the compound in models of prostate and lung...